Study on HRD test and PARP inhibitor for ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at a genetic test called HRD to see if it can predict how well PARP inhibitors (a type of targeted therapy) work for ovarian cancer patients. It is for women who have been treated with platinum chemotherapy and are now on PARP inhibitor maintenance therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, first diagnosed after January 2015.
- You are a woman aged 18 or older.
- You have been treated with platinum chemotherapy and are now on a PARP inhibitor maintenance therapy (started by January 2024).
- Your CA125 level is stable, and you have a good performance status (ECOG 0-2) with normal heart, liver, and kidney function.
- You have not had any other cancer in the last 5 years.
- You do not have severe heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how a gene test called HRD (which looks for DNA repair problems in your tumor) relates to how well a type of drug called a PARP inhibitor works for ovarian cancer. It aims to help doctors choose the best treatment for each person.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Hear when a new Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.